Catarina Guimarães-Teixeira

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Topics

Dna Damage Response

Transforming Growth Factor

Top Venues

Molecular oncology

Journal of experimental & clinical cancer research : CR

Cellular oncology (Dordrecht)

This page only lists publications with an associated author ORCID identifier.

Publications

Cláudia Martins-Lima, Vera Miranda-Gonçalves, João Lobo, Vera Constâncio, Pedro Leite-Silva, Catarina Guimarães-Teixeira, Sara Monteiro-Reis, José Pedro Sequeira, Mariana Cantante, Céline S Gonçalves, Bruno M Costa, Rui M Henrique, Carmen Jerónimo
Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. Cellular oncology (Dordrecht) 45 (1) (2022)
Catarina Guimarães-Teixeira, João Lobo, Vera Miranda-Gonçalves, Daniela Barros-Silva, Cláudia Martins-Lima, Sara Monteiro-Reis, José Pedro Sequeira, Isa Carneiro, Margareta P Correia, Rui M Henrique, Carmen Jerónimo
Downregulation of m 6 A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. Molecular oncology 16 (9) (2022)
João Lobo, Vera Constâncio, Catarina Guimarães-Teixeira, Pedro Leite-Silva, Vera Miranda-Gonçalves, José Pedro Sequeira, Laura Pistoni, Rita Guimarães, Mariana Cantante, Isaac Braga, Joaquina Maurício, Leendert H J Looijenga, Rui M Henrique, Carmen Jerónimo
Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Molecular oncology 15 (4) (2021)
Vera Miranda-Gonçalves, João Lobo, Catarina Guimarães-Teixeira, Daniela Barros-Silva, Rita Guimarães, Mariana Cantante, Isaac Braga, Joaquina Maurício, Christoph Oing, Friedemann Honecker, Daniel Nettersheim, Leendert H J Looijenga, Rui M Henrique, Carmen Jerónimo
The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. Journal of experimental & clinical cancer research : CR 40 (1) (2021)